FrancophonIA/ELRC3.0 huggingface dataset:
English: Post marketing experience: very rare cases of high anion gap metabolic acidosis, when flucloxacillin is used concomitantly with paracetamol, generaly in the presence of risk factors (see section 4.4.)
Maltese: Esperjenza ta' wara t-tqegħid fis-suq: każijiet rari ħafna ta' aċidożi metabolika b'distakk kbir bejn lanjoni, meta flucloxacillin jintuża flimkien ma' paracetamol, ġeneralment fil-preżenza ta' fatturi ta' riskju (ara sezzjoni 4.4.)
English: After co-administration of flucloxacillin and paracetamol, a close monitoring is recommended in order to detect the appearance of acid-base disorders, namely HAGMA, including the search of urinary 5oxoproline.
Maltese: Wara l-għoti flimkien ta' flucloxacillin u paracetamol, huwa rrakkomandat li jsir monitoraġġ mill-qrib sabiex jiġu skoperti s-sinjali ta' disturbi tal-aċidu/bażi, jiġifieri HAGMA, inkluż it-tiftix ta' 5-oxoproline fl-awrina.
English: Rare: skin eruption that is characterised by the rapid appearance of areas of red skin studded with small pustules (small blisters filled with white/yellow fluid).
Maltese: Rari: eruzzjoni tal-ġilda karatterizzata mit-tfaċċar rapidu ta' żoni ta' ġilda ħamra b'pustuli żgħar (infafet żgħar mimlija bi fluwidu abjad/isfar).
English: The occurrence at the treatment initiation of a feverish generalised erythema associated with pustula may be a symptom of acute generalised exanthematous pustulosis (AGEP) (see section 4.8).
Maltese: L-okkorrenza ta' eritema ġeneralizzata bid-deni assoċjata ma' ponot fil-bidu tal-kura, tista' tkun sintomu ta' pustulożi esantematika ġeneralizzata akuta (AGEP) (ara sezzjoni 4.8).
English: Skin and subcutaneous tissue disorders Not known: acute generalised exanthematous pustulosis (AGEP)
Maltese: Disturbi fil-ġilda u fit-tessuti ta' taħt il-ġilda Mhux magħruf: pustulożi esantematika ġeneralizzata akuta (AGEP)
English: Acute generalised exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome, toxic epidermal necrolysis and drug rash with eosinophilia and systemic symptoms (DRESS)), clarithromycin therapy should be discontinued immediately and appropriate treatment should be urgently initiated.
Maltese: F'każ ta' reazzjonijiet serji akuti ta' sensittività eċċessiva, bħal anafilassi, reazzjonijiet avversi serji talġilda (SCAR) (eż. Pustulożi esantematika ġeneralizzata akuta (AGEP), is-Sindrome ta' StevensJohnson, nekroliżi epidermali tossika u raxx minħabba l-mediċina b'eosinofilja u sintomi sistemiċi (DRESS)), it-terapija b'clarithromycin għandha titwaqqaf minnufih u għandha tinbeda kura xierqa b'urġenza.
English: Interaction with other medicinal products and other forms of interaction Caution should be taken when flucloxacillin is used concomitantly with paracetamol as concurrent intake has been associated with high anion gap metabolic acidosis, especially in patients with risk factors.
Maltese: Interazzjoni ma' prodotti mediċinali oħra u forom oħra ta' interazzjoni Għandha tintuża kawtela meta flucloxacillin jintuża flimkien ma' paracetamol minħabba li t-teħid konkomitanti kien assoċjat ma' aċidożi metabolika b'distakk kbir bejn l-anjoni, speċjalment f'pazjenti b'fatturi ta' riskju.
English: Very rare cases of blood and fluid abnormality (high anion gap metabolic acidosis) which occurs when there is an increase in plasma acidity, when flucloxacillin is used concomitantly with paracetamol, generaly in the presence of risk factors (see section 2).
Maltese: Każijiet rari ħafna ta' abnormalità fid-demm u fil-fluwidi (aċidożi metabolika b'distakk kbir bejn lanjoni) li sseħħ meta jkun hemm żieda fl-aċidità tal-plażma, meta flucloxacillin jintuża flimkien ma' paracetamol, ġeneralment fil-preżenza ta' fatturi ta' riskju (ara sezzjoni 2).
English: These may all be symptoms of a serious and potentially fatal brain condition known as progressive multifocal leukoencephalopathy (PML).
Maltese: Dawn kollha jistgħu jkunu sintomi ta' kundizzjoni serja u potenzjalment fatali tal-moħħ magħrufa bħala lewkoenċefalopatija multifokali progressiva (PML).
English: If a widespread, severe skin rash occurs, including skin blistering or peeling, as well as signs of flu and fever (Stevens-Johnson syndrome), a general unwell feeling, fever, chills and muscle aches (toxic epidermal necrolysis), or a red, scaly rash with bumps under the skin and blisters (acute generalised exanthematous pustulosis), refer to a doctor immediately since these skin effects may be lifethreatening.
Maltese: Fil-każ ta' raxx serju mifrux fuq il-ġilda, inkluż bi nfafet jew tqaxxir tal-ġilda, kif ukoll sinjali ta' influwenza u deni (sindrome ta' Stevens-Johnson), sensazzjoni ta' telqa ġenerali, deni, tkexkix ta' bard u uġigħ fil-muskoli (nekroliżi epidermali tossika), jew raxx aħmar, bil-qoxra u bil-boċċi taħt il-ġilda u nfafet (pustulożi esantematika ġeneralizzata akuta), kellem tabib minnufih peress li dawn l-effetti talġilda jistgħu jkunu ta' periklu għall-ħajja.
English: As with other macrolides, rare serious allergic reactions, including acute generalised exanthematous pustulosis (AGEP) have been reported.
Maltese: Bħal fil-każ ta' makrolidi oħra, ġew irrapportati reazzjonijiet allerġiċi serji rari, fosthom pustulożi esantematika ġeneralizzata akuta (AGEP).
English: Severe bullous reactions
Maltese: Reazzjonijiet bullużi serji
English: Some patients with spirochete infections may experience a Jarisch-Herxheimer reaction shortly after doxycycline treatment is started.
Maltese: Xi pazjenti b'infezzjonijiet bi spirochete jistgħu jesperjenzaw reazzjoni ta' Jarisch-Herxheimer ftit wara li tinbeda l-kura b'doxycycline.
English: EMA/692664/2014 EMEA/H/C/000707
Maltese: EMEA/H/C/000707
English: The full EPAR for Prezista can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: L-EPAR sħiħ ta' Prezista jinsab fuq is-sit elettroniku tal-Aġenzija ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: It is available as tablets (75, 150, 300, 400, 600, and 800 mg) and as an oral suspension (100 mg/ml).
Maltese: Jiġi bħala pilloli (75, 150, 300, 400, 600 u 800 mg) u bħala sospensjoni orali (100 mg/ml).
English: The active substance in Prezista, darunavir, is a protease inhibitor.
Maltese: Is-sustanza attiva ta' Prezista, id-darunavir, hija inibitur tal-proteażi.
English: In adults, the most common side effects with Prezista are diarrhoea, ‘immune reconstitution syndrome', nausea (feeling sick), pyrexia (fever) and rash.
Maltese: Fl-adulti, l-effetti sekondarji l-aktar komuni bi Prezista huma dijarea, ‘is-sindromu ta' rikostruzzjoni immunitarja', nawżja (dardir), piressija (deni) u raxx.
English: The 300- and 600-mg tablets contain a colouring agent called sunset yellow (E110), which can cause allergies.
Maltese: Il-pilloli ta' 300 mg u ta' 600 mg fihom sustanza koloranti bl-isem ta' sunset yellow (E110) li tista' tikkawża allerġiji.
English: Either ritonavir or cobicistat is used with Prezista as a ‘booster'.
Maltese: Ritonavir jew cobicistat jintużaw ma' Prezista bħala ‘booster'.
English: Prezista is a medicine that contains the active substance darunavir.
Maltese: Prezista huwa mediċina li fiha s-sustanza attiva darunavir.
English: This is a summary of the European public assessment report (EPAR) for Prezista.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Prezista.
English: The oral suspension is available for patients unable to swallow the tablets.
Maltese: Is-sospensjoni orali hija disponibbli għal pazjenti li ma jistgħux jibilgħu il-pilloli.
English: Prezista 800 mg once a day was as effective as Prezista 600 mg twice a day in patients who had been treated before: after 48 weeks, 72% of the patients taking Prezista 800 mg once day had viral loads below 50 copies/ml (212 out of 294) compared with 71% of those taking Prezista 600 mg twice a day (210 out of 296).
Maltese: Prezista 800 mg kuljum kien effikaċi daqs Prezista 600 mg darbtejn kuljum f'pazjenti li kienu ġew ittrattati qabel: wara 48 ġimgħa, 72% tal-pazjenti li kienu qed jieħdu 800 mg Prezista darba kuljum kellhom tagħbijiet virali taħt il-50 kopja/ml (212 minn 294) meta mqabbla ma' 71% ta' dawk li kienu qed jieħdu 600 mg Prezista darbtejn kuljum (210 minn 296).
English: After 48 weeks, 84% of the patients taking ritonavir-boosted Prezista had viral loads below 50 copies/ml (287 out of 343) compared with 78% of those taking ritonavir-boosted lopinavir (271 out of 346).
Maltese: 50 kopja/ml (287 minn 343) meta mqabbla ma' 78% ta' dawk li kienu qed jieħdu lopinavir imsaħħaħ b'ritonavir (271 minn 346).
English: Side effects are similar in children and adolescents.
Maltese: Fit-tfal u fl-adolexxenti l-effetti sekondarji huma simili.
English: Prezista in combination with the booster cobicistat was evaluated in a study in 313 adult patients all of whom received 800 mg Prezista and 150 mg cobicistat once a day, in addition to two other HIV medicines.
Maltese: Prezista flimkien mal-booster cobicistat kien evalwat fi studju fi 313-il adult li kollha rċevew 800 mg Prezista u 150 mg cobicistat darba kuljum, flimkien ma' żewġ mediċini oħrajn tal-HIV.
English: Why has Prezista been approved?
Maltese: Għaliex ġie approvat Prezista?
English: In adults who had received many anti-HIV medicines in the past, 70% of those taking the approved dose of ritonavir-boosted Prezista (92 out of 131) had at least a 90% reduction in viral load after 24 weeks, compared with 21% of those taking the comparator protease inhibitors (26 out of 124).
Maltese: Fl-adulti li kienu diġà rċevew ħafna mediċini kontra l-HIV fil-passat, 70% ta' dawk ittrattati bid-doża approvata ta' Prezista msaħħaħ b'ritonavir (92 minn 131) kellhom millinqas 90% tnaqqis fit-tagħbija virali wara 24 ġimgħa meta mqabbla ma' 21% tal-pazjenti li kienu ttrattati bl-inibituri tal-proteażi tat-tqabbil (26 minn 124).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Prezista on 12 February 2007.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Prezista valida fl-Unjoni Ewropea kollha fit-12 ta' Frar 2007.
English: The fifth study involved 590 adults who had been treated before and compared Prezista 800 mg once a day with Prezista 600 mg twice a day.
Maltese: Il-ħames studju involva 590 adult li kienu ġew ittrattati qabel u qabbel 800 mg Prezista darba kuljum ma' 600 mg Prezista darbtejn kuljum.
English: In adults who had not been treated before, Prezista was as effective as lopinavir.
Maltese: Fl-adulti li qatt ma kienu ġew ittrattati qabel, Prezista kien effikaċi daqs lopinavir.
English: How has Prezista been studied?
Maltese: Kif ġie studjat Prezista?
English: One study compared ritonavir-boosted Prezista 800 mg once a day with ritonavir-boosted lopinavir (another protease inhibitor) in 691 adults who had not been treated for HIV before.
Maltese: Studju minnhom qabbel Prezista 800 mg imsaħħaħ (boosted) b'ritonavir darba kuljum ma' lopinavir (inibitur tal-proteażi ieħor) imsaħħaħ b'ritonavir f'691 adult li ma kinux ġew ittrattati għall-HIV qabel.
English: One study compared ritonavir-boosted Prezista with ritonavir-boosted lopinavir in 604 patients who had taken some anti-HIV medicines in the past.
Maltese: Studju minnhom qabbel Prezista msaħħaħ b'ritonavir ma' lopinavir imsaħħaħ b'ritonavir f'604 pazjenti li filpassat kienu diġà ħadu xi mediċini kontra l-HIV.
English: Prezista is used together with low-dose ritonavir and other HIV medicines to treat adults and children aged three years or over who are infected with human immunodeficiency virus (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Maltese: Prezista jintuża flimkien ma' doża baxxa ta' ritonavir u mediċini antivirali oħrajn ta' kontra l-HIV biex jittrattaw adulti u tfal minn tliet snin 'il fuq li huma infettati bil-virus tal-immunodefiċjenza umana (HIV-1), virus li jikkawża s-sindromu mill-immunodefiċjenza akkwiżita (AIDS).
English: In the study looking at Prezista with cobicistat, around 81% (253 out of 313) of patients had viral loads below 50 copies/ml after 48 weeks.
Maltese: Fl-istudju li ffoka fuq Prezista ma' cobicistat, madwar 81% (253 minn 313) tal-pazjenti kellhom tagħbijiet virali taħt il-50 kopja/ml wara 48 ġimgħa.
English: A risk management plan has been developed to ensure that Prezista is used as safely as possible.
Maltese: Pjan ta' ġestjoni tar-riskju ġie żviluppat biex jassigura li Prezista jintuża bl-aktar mod sigur possibbli.
English: In patients who had taken some anti-HIV medicines in the past, 77% of those taking ritonavir-boosted Prezista had viral loads below 400 copies/ml after 48 weeks, compared with 68% of those taking ritonavir-boosted lopinavir.
Maltese: Fil-pazjenti li fil-passat kienu diġà ħadu xi mediċini kontra l-HIV, 77% ta' dawk ittrattati bi Prezista msaħħaħ b'ritonavir kellhom tagħbijiet virali taħt l-400 kopja/ml wara 48 ġimgħa meta mqabbla ma' 68% ta' dawk ittrattati b'lopinavir imsaħħaħ b'ritonavir.
English: What is the risk associated with Prezista?
Maltese: Għal xiex jintuża Prezista?
English: Prezista was also effective in previously treated children: 74% of the previously treated children aged above six years (59 out of 80) had at least a 90% reduction in viral loads after 24 weeks of treatment; 81% of those aged between three and six (17 out of 21) had viral loads below 50 copies/ml after 48 weeks.
Maltese: Prezista kien effettiv ukoll fi tfal li kienu rċevew kura fil-passat: 74% tat-tfal minn sitt snin 'il fuq li kienu diġà ngħataw kura (59 minn 80) kellhom mill-inqas 90% tnaqqis fit-tagħbijiet virali wara 24 ġimgħa ta' kura; 81% tat-tfal bejn tlieta u sitt snin (17 minn 21) kellhom tagħbijiet virali taħt il50 kopja/ml wara 48 ġimgħa.
English: When the enzyme is blocked, the virus does not reproduce normally and its rate of replication slows down.
Maltese: Meta l-enzima tiġi mblokkata, il-virus ma jirriproduċix ruħu b'mod normali, u jittardja r-rata ta' multiplikazzjoni.
English: In adults, Prezista is also used with another medicine, cobicistat, in combination with other HIV medicines to treat HIV-1 infection.
Maltese: Fl-adulti, Prezista jintuża wkoll ma' mediċina oħra, cobicistat, flimkien ma' mediċini tal-HIV oħra biex jittrattaw infezzjoni HIV-1.Il-mediċina tista' tinkiseb biss b'riċetta ta' tabib.
English: It blocks an enzyme called protease, which is involved in the reproduction of HIV.
Maltese: Din timblokka enzima li tissejjaħ proteażi, li għandha sehem fir-riproduzzjoni tal-HIV.
English: This summary was last updated in 10-2014.
Maltese: Dan is-sommarju kien aġġornat l-aħħar fi: 10-2014.
English: What measures are being taken to ensure the safe and effective use of Prezista?
Maltese: X'miżuri qegħdin jittieħdu biex jassiguraw użu sigur u effettiv ta' Prezista?
English: The other two studies compared ritonavir-boosted Prezista with other protease inhibitors chosen on the basis of the patient's previous treatments and predicted response, in a total of 628 patients who had taken many anti-HIV medicines in the past.
Maltese: Iż-żewġ studji l-oħra qabblu Prezista msaħħaħ b'ritonavir ma' inibituri tal-proteażi oħra magħżula abbażi tat-trattamenti preċedenti tal-pazjent u rrispons imbassar, f'total ta' 628 pazjent li fil-passat kienu ħadu ħafna mediċini kontra l-HIV.
English: Prezista must not be taken by patients who have severely reduced liver function, or who are taking certain other medicines which may decrease blood levels of darunavir, ritonavir or cobicistat, and therefore cause a lack of effect.
Maltese: Prezista ma għandux jittieħed minn pazjenti li għandhom indeboliment serju tal-fwied, jew li qed jieħdu ċerti mediċini oħrajn li jistgħu jnaqqsu l-livelli ta' darunavir, ritonavir jew cobicistat fid-demm, u għalhekk jikkawżaw nuqqas ta' effett.
English: Ritonavir-boosted Prezista has also been studied in 101 previously treated children aged between three and 18 years and 12 previously untreated children aged between 12 to 18 years who weighed at least 40 kg.
Maltese: Prezista msaħħaħ bir-ritonavir ġie studjat ukoll f'101 tifel u tifla ta' bejn it-tliet snin u t-18-il sena u 12il tifel u tifla li qatt ma kienu rċevew kura li kellhom bejn it-12 u t-18-il sena li kienu jiżnu mill-inqas 40 kg.
English: In the study of previously untreated children, 83% (10 out of 12) had viral loads below 50 copies/ml after 48 weeks of treatment.
Maltese: Fl-istudju ta' tfal li ma kinux ingħataw kura fil-passat, 83% (10 minn 12) kellhom tagħbijiet virali taħt il-50 kopja /ml wara 48 ġimgħa ta' kura.
English: For previously untreated children aged from 3 to 17 years and weighing at least 15 kg, the recommended dose varies between 600 and 800 mg once daily depending on the body weight.
Maltese: Għat-tfal li għandhom bejn 3 snin u 17-il sena li qatt ma ngħataw kura qabel u li jiżnu mill-inqas 15-il kg, id-doża rakkomandata tvarja bejn 600 u 800 mg darba kuljum jiddependi mill-piż tal-ġisem.
English: Patients who are allergic to this agent may need to take the lower strength tablets, which do not contain sunset yellow.
Maltese: Il-pazjenti li jkunu allerġiċi għal din s-sustanza jistgħu jeħtieġu li jieħdu l-pilloli b'dożaġġ anqas qawwi, li ma fihomx sunset yellow.
English: How does Prezista work?
Maltese: X'inhu Prezista?
English: Three studies involved adults who had been treated before who received 600 mg Prezista twice a day.
Maltese: Tliet studji involvew adulti li kienu ġew ittrattati qabel li ħadu 600 mg Prezista darbtejn kuljum.
English: In adults, Prezista has been studied in six main studies.
Maltese: Fl-adulti, Prezista ġie studjat f'sitt studji ewlenin.
English: Prezista does not cure HIV infection or AIDS, but it may delay or reverse the damage to the immune system and the development of infections and diseases associated with AIDS.
Maltese: Prezista ma jfejjaqx infezzjoni mill-HIV jew tal-AIDS, iżda jista' jittardja jew ireġġa' lura lħsara lis-sistema immunitarja u l-iżvilupp ta' infezzjonijiet u mard assoċjat mal-AIDS.
English: This allows a lower dose of darunavir to be used for the same antiviral effect.
Maltese: Dan jippermetti l-użu ta' doża anqas ta' darunavir għall-istess effett antivirali.
English: The CHMP decided that Prezista's benefits are greater than its risks and recommended that it be given marketing authorisation.
Maltese: Is-CHMP iddeċieda li l-benefiċċji ta' Prezista huma akbar mir-riskji tiegħu u rrakkomanda li jingħata awtorizzazzjoni għat-tqegħid fis-suq.
English: Previously treated children may be given similar once-daily doses, provided that their disease is not resistant to Prezista, but treatment is usually with a dose between 380 and 600 mg twice daily, depending on their weight.
Maltese: Tfal li ġew trattati qabel jistħu jingħataw dożaġġi simili darba kulum, dejjem jekk il-marda tagħhom mhix reżistenti għal Prezista, iżda t-trattament ġeneralment ikun b'doża bejn 380 u 600 mg darbtjen kuljum jiddependi mill-piż.
English: What benefit has Prezista shown during the studies?
Maltese: Liema benefiċċju wera Prezista matul l-istudji?
English: (Invented) name Strength Pharmaceutical Form Route of Administration
Maltese: Numru ta'l-EU Isem (inventat) Qawwa Għamla farmaċewtika
English: Oral use bottle (HDPE) 30 tablets
Maltese: Flixkun (HDPE)
English: Film-coated tablet
Maltese: Użu orali
English: EMA/273849/2014 EMEA/H/C/000267
Maltese: EMEA/H/C/000267
English: Azopt brinzolamide
Maltese: Azopt brinżolamur
English: The full EPAR for Azopt can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Dorzolamide led to decreases of between 4.3 and 4.9 mmHg.
Maltese: Dorżolamur wassal għal tnaqqis ta' bejn 4.3 u 4.9 mmHg.
English: Azopt caused a reduction in eye pressure of between 2.7 and 5.7 mmHg over 18 months, compared with a reduction of between 5.2 and 6.0 mmHg with timolol.
Maltese: Azopt ikkawża tnaqqis fil-pressjoni fl-għajn ta' bejn 2.7 u 5.7 mmHg fuq perjodu ta' 18-il xahar, meta mqabbel ma' tnaqqis ta' bejn 5.2 u 6.0 mmHg b'timolol.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Azopt on 9 March 2000.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Azopt valida fl-Unjoni Ewropea kollha fid-9 ta' Marzu 2000.
English: This is a summary of the European public assessment report (EPAR) for Azopt.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Azopt.
English: The eye pressure was at least 21 mmHg in all of the patients at the start of the studies (above the normal range of 10 to 21 mmHg).
Maltese: Il-pressjoni fl-għajn kienet mill-inqas 21 mmHg fil-pazjenti kollha filbidu tal-istudji (‘il fuq mill-firxa normali ta' 10 sa 21 mmHg).
English: This summary was last updated in 05-2014.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'05-2014.
English: Azopt has been studied in seven main studies including a total of 2,173 patients with open-angle glaucoma or ocular hypertension.
Maltese: Azopt ġie studjat f'seba' studji prinċipali li inkludew total ta' 2,173 pazjent bi glawkoma b'angolu miftuħ jew ipertensjoni okulari.
English: The active substance in Azopt, brinzolamide, is a carbonic anhydrase inhibitor.
Maltese: Is-sustanza attiva f'Azopt, brinżolamur, hija inibitur anidrasju tal-karbonju.
English: Other information about Azopt
Maltese: Aktar informazzjoni dwar Azopt
English: What is the risk associated with Azopt?
Maltese: X'riskju huwa assoċjati ma' Azport?
English: A risk management plan has been developed to ensure that Azopt is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiżgura li Azopt jintuża bl-aktar mod sigur possibbli.
English: Two of the studies compared adding Azopt, dorzolamide or placebo (a dummy treatment) to timolol, and the final two studies compared Azopt used twice a day with timolol, when they were used as an add-on to travoprost (a prostaglandin analogue).
Maltese: Fi tlieta minn dawn l-istudji, Azopt, użat waħdu darbtejn jew tliet darbiet kuljum, tqabbel ma' timolol (imblukkatur beta) u ma' dorżolamur (inibitur anidrasju tal-karbonju ieħor).
English: What is Azopt?
Maltese: Għal xiex jintuża Azopt?
English: Azopt was as effective as dorzolamide when used on its own or as an add-on to timolol, with decreases in pressure of between 3.4 and 5.7 mmHg.
Maltese: Azopt kien effettiv daqs dorżolamur meta użat waħdu jew bħala żieda ma' timolol, bi tnaqqis filpressjoni ta' bejn 3.4 u 5.7 mmHg.
English: The most common side effects with Azopt (seen in more than 1 patient in 20) are dysgeusia (a bitter or unusual taste in the mouth) and temporary blurring of vision.
Maltese: L-effetti sekondarji l-aktar komuni b'Azopt (li dehru f'aktar minn pazjent 1 minn kull 20) huma disgewsja (togħma qarsa jew mhux tas-soltu fil-ħalq) u vista mċajpra temporanjament.
English: Why has Azopt been approved?
Maltese: Għaliex ġie approvat Azopt?
English: It works by blocking an enzyme called carbonic anhydrase, which produces bicarbonate in the body.
Maltese: Din taħdem billi timblokka enzima msejħa anidrasju tal-karbonju, li tipproduċi l-bikarbonat fil-ġisem.
English: Bicarbonate is required for the production of the aqueous humour (the watery fluid in the eye).
Maltese: Għall-produzzjoni tal-umur akwatiku (aqueous humour - il-fluwidu likwidu fl-għajn) jeħtieġ li jkun hemm il-bikarbonat.
English: How has Azopt been studied?
Maltese: Kif ġie studjat Azopt?
English: Azopt is used as an add-on to beta blockers or prostaglandin analogues (other medicines used for these conditions), or on its own in patients who cannot take or do not respond to beta blockers.
Maltese: Azopt jintuża bħala żieda ma' imblokkaturi beta jew analogi prostaglandini (mediċini oħra użati f'dawn il-kondizzjonijiet), jew waħdu f'pazjenti li ma jistgħux jieħdu jew ma jirrispondux tajjeb għall-imblokkaturi beta.
English: Raised pressure inside the eye causes damage to the retina (the light-sensitive surface at the back of the eye) and to the optic nerve (the nerve that sends signals from the eye to the brain).
Maltese: Pressjoni għolja fl-għajn tikkawża ħsara fir-retina (il-membrana sensittiva għad-dawl li tiksi l-parti ġewwinija tal-għajn) u lin-nerv ottiku (in-nerv li jibgħat is-sinjali mill-għajn għall-moħħ).